Last 31 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.98 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.16 | 11.43 | 41.21 | 14.72 | 65.18 | 145.85 | 28.10 | 13.57 | 35.97 | 37.14 | 16.90 | 32.58 | 69.03 |
| — | -92.2% | +46.6% | +8.5% | +81.2% | +292.7% | +66.3% | -58.4% | -47.9% | -34.6% | -40.5% | -61.3% | -40.6% | |
| P/B Ratio | 0.42 | 0.87 | 0.72 | 0.79 | 1.22 | 1.88 | 1.20 | 2.98 | 2.07 | 1.91 | 3.50 | 2.62 | 3.25 |
| — | -53.8% | -40.3% | -73.3% | -41.0% | -1.7% | -65.6% | +13.4% | -36.3% | -19.9% | +119.1% | -33.3% | -35.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 5.70 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Bicycle Therapeutics plc's operating margin was -558.6% in Q3 2025, up 2407.2 pp QoQ and up 1827.2 pp YoY. The trailing four-quarter average of -1513.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 106.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -390.3% | 100.0% | -2332.5% | -474.0% | -1412.2% | -1605.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | +106.2% | -2432.5% | -574.0% | -1512.2% | -1705.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -595.0% | -558.6% | -2965.8% | -703.7% | -1824.8% | -2385.9% | -498.3% | -162.4% | -1017.4% | -949.1% | -378.3% | -853.8% | -1011.3% |
| — | +76.6% | -495.2% | -333.3% | -79.4% | -151.4% | -31.7% | +81.0% | -0.6% | +3.0% | +39.3% | -20.4% | -111.6% | |
| Net Margin | -479.2% | -503.7% | -2703.8% | -608.9% | -1398.4% | -1898.4% | -425.3% | -136.0% | -921.0% | -932.3% | -373.8% | -797.9% | -941.2% |
| — | +73.5% | -535.8% | -347.7% | -51.8% | -103.6% | -13.8% | +83.0% | +2.1% | +0.0% | +39.0% | -11.7% | -96.8% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.0% | -9.2% | -11.2% | -7.9% | -6.4% | -6.0% | -6.5% | -7.3% | -12.5% | -15.7% | -18.4% | -15.2% | -10.7% |
| — | -54.1% | -73.1% | -8.4% | +48.8% | +62.0% | +64.8% | +51.9% | -16.6% | -66.3% | -120.0% | -86.5% | -53.4% | |
| ROA | -21.8% | -7.4% | -9.2% | -6.6% | -5.3% | -4.9% | -5.0% | -4.7% | -8.0% | -9.1% | -9.6% | -9.3% | -7.2% |
| — | -49.7% | -85.4% | -42.0% | +33.3% | +45.8% | +48.6% | +50.0% | -9.9% | -38.9% | -62.8% | -58.6% | -52.8% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 37.7% YoY to 10.66x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 | 0.12 | 0.12 | 0.11 | 0.21 | 0.20 | 0.16 |
| — | -30.4% | -75.6% | -90.0% | -90.1% | -87.9% | -77.1% | -39.5% | -26.0% | -27.8% | +46.2% | +42.6% | +27.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.81 | 10.66 | 10.39 | 14.86 | 13.81 | 17.13 | 14.77 | 10.42 | 8.08 | 8.65 | 5.65 | 7.19 | 6.92 |
| — | -37.7% | -29.7% | +42.6% | +70.9% | +98.1% | +161.4% | +44.9% | +16.7% | -5.8% | -42.8% | -40.7% | -45.3% | |
| Quick Ratio | 13.81 | 10.66 | 10.39 | 14.86 | 13.81 | 17.13 | 14.77 | 10.42 | 8.08 | 8.65 | 5.65 | 7.19 | 6.92 |
| — | -37.7% | -29.7% | +42.6% | +70.9% | +98.1% | +161.4% | +44.9% | +16.7% | -5.8% | -42.8% | -40.7% | -45.3% | |
| Interest Coverage | -121.31 | -1489.80 | -1603.74 | -1376.55 | -1301.21 | -1934.73 | -56.61 | -38.63 | -66.14 | -62.40 | -52.51 | -51.74 | -39.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBicycle Therapeutics plc's current P/E is -2.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bicycle Therapeutics plc's current operating margin is -595.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bicycle Therapeutics plc's business trajectory between earnings reports.